Cannell & Co. purchased a new position in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 12,600 shares of the biopharmaceutical company’s stock, valued at approximately $267,000. Several other institutional investors have also […]
– Late-breaker SOLSTICE data abstract accepted for poster presentation at the European Association for the Study of the Liver Congress 2024 –
– Two additional hepatitis program data readouts.
Xencor (NASDAQ:XNCR) Sees Unusually-High Trading Volume theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
– Total revenues of $881 million in the first quarter
– Jakafi® net product revenues of $572 million in Q1 24, total paid patients increased +5% Y/Y; reiterating full year 2024 guidance of.
MorphoSys AG Reports First Quarter 2024 Financial Results finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.